Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years

Blood (2017) 130 (Supplement 1): 486.

https://doi.org/10.1182/blood.V130.Suppl_1.486.486

Published: 2017

Journal Articles

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

Clémentine Sarkozy, John Francis Seymour, Christophe Ferme, Dolores Caballero, Hervé Ghesquieres, Sirpa Leppa, Richard Delarue, Lars Moller Pedersen, Christiane Mounier, Maria Gomes Da Silva, Catherine Chassagne-Clement, Marie Maerevoet, Gilles Salles

Blood (2014) 123 (17): 2740–2742.

https://doi.org/10.1182/blood-2014-02-553693

Published: 2014

Journal Articles

Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy

Blood (2013) 122 (21): 509.

https://doi.org/10.1182/blood.V122.21.509.509

Published: 2013

Journal Articles

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

Hervé Ghesquières, Guillaume Cartron, John Francis Seymour, Marie-Hélène Delfau-Larue, Fritz Offner, Pierre Soubeyran, Aurore Perrot, Pauline Brice, Réda Bouabdallah, Anne Sonet, Jehan Dupuis, Olivier Casasnovas, John Vincent Catalano, Alain Delmer, Fabrice Jardin, Aurélie Verney, Peggy Dartigues, Gilles Salles

Blood (2012) 120 (13): 2650–2657.

https://doi.org/10.1182/blood-2012-05-431825

Published: 2012

Journal Articles

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Blood (2011) 118 (14): 3765–3776.

https://doi.org/10.1182/blood-2011-01-330126

Published: 2011

Includes: Supplemental data

Journal Articles

Comparison of Platelet-Activating Potential of Bevacizumab+VEGF and Aflibercept+VEGF Complexes

Todd Meyer, PhD., Liza Robles-Carrillo, M.S., Hina Desai, M.S., Meghan Hatfield, M.S., Mildred Amaya, M.S., John Francis, PhD, Ali Amirkhosravi, PhD.

Blood (2010) 116 (21): 3200.

https://doi.org/10.1182/blood.V116.21.3200.3200

Published: 2010

Journal Articles

CDP7657, and Other Anti-CD40L Antibody Formats Lacking a Functional Fc Region, Do Not Cause Platelet Activation In Vitro

Ali Amirkhosravi, PhD., Todd Meyer, PhD., Olivier Harari, PhD., Linda Burkly, PhD., Lihe Su, PhD., Yen-Ming Hsu, PhD., Timothy Bourne, PhD., Ian Wakefield, PhD., Christopher Peters, PhD., Anthony Shock, PhD., John Francis, PhD

Blood (2010) 116 (21): 5128.

https://doi.org/10.1182/blood.V116.21.5128.5128

Published: 2010

Journal Articles

Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.

Blood (2010) 116 (21): 1788.

https://doi.org/10.1182/blood.V116.21.1788.1788

Published: 2010

Journal Articles

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

Pierre Fenaux, Aristotle Giagounidis, Dominik Selleslag, MD, Odile Beyne-Rauzy, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Moshe Mittelman, MD, Petra Muus, MD, PhD, Peter te Boekhorst, MD, PhD, Guillermo Sanz, MD, PhD, Consuelo del Cañizo, Agnes Guerci-Bresler, Brigitte Schlegelberger, M.D., Carlo Aul, Hans Kreipe, MD, Gudrun Goehring, Robert Knight, MD, John Francis, Tommy Fu, Eva Hellstrom-Lindberg, MD, PhD

Blood (2009) 114 (22): 944.

https://doi.org/10.1182/blood.V114.22.944.944

Published: 2009

Journal Articles

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Blood (2008) 112 (11): 325.

https://doi.org/10.1182/blood.V112.11.325.325

Published: 2008

Journal Articles

The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantilly Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study

Kirsten Herbert, MBBS, FRACP, PhD, Max Wolf, MBBS, FRACP, FRCPA, Dennis Carney, MBBS, FRACP, FRCPA, David Alan Westerman, MBBS, FRACP, FRCPA, Henry Januszewicz, MBBS, FRACP, FRCPA, Simon Harrison, MBBS, PhD, David Ritchie, MBChB, FRACP, FRCPA, PhD, H. Miles Prince, John Francis Seymour, MBBS, FRACP, PhD

Blood (2008) 112 (11): 3596.

https://doi.org/10.1182/blood.V112.11.3596.3596

Published: 2008

Journal Articles

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.

Susan Branford, Rebecca Lawrence, Andrew Grigg, John Francis Seymour, MBBS, Anthony Schwarer, Christopher Arthur, Zbigniew Rudzki, Timothy Hughes

Blood (2008) 112 (11): 2113.

https://doi.org/10.1182/blood.V112.11.2113.2113

Published: 2008

Journal Articles

Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.

Michael J. Dickinson, MBBS, Rosemary Hoyt, BN, Andrew Roberts, MBBS PhD, Andrew Grigg, MBBS, John Francis Seymour, MBBS PhD, Jeff Szer, MBBS BSc BMedSci, H. Miles Prince, MBBS(Hons)MD, David Ritchie, MBChB PhD

Blood (2007) 110 (11): 5115.

https://doi.org/10.1182/blood.V110.11.5115.5115

Published: 2007

Journal Articles

A Prospective Study of the Prognostic Impact of 18 [F]-FDG-PET and Molecular Response in Patients with Relapsed Indolent Non-Hodgkin Lymphoma (NHL) Following Iodine-131-Rituximab Radio-Immunotherapy (RIT).

Mark J. Bishton, MB, ChB, Rod Hicks, David Alan Westerman, Miles Prince, Max Wolf, John Francis Seymour

Blood (2007) 110 (11): 3421.

https://doi.org/10.1182/blood.V110.11.3421.3421

Published: 2007

Journal Articles

Repeat Treatment with Iodine-131-Rituximab Is Safe and Effective in Patients with Relapsed Indolent B-Cell Non-Hodgkin Lymphoma (NHL) Who Had Previously Responded to This Therapy.

Mark J. Bishton, MB, ChB, Michael F. Leahy, Rod J. Hicks, J. Harvey Turner, Ad McQuillan, John Francis Seymour

Blood (2007) 110 (11): 3413.

https://doi.org/10.1182/blood.V110.11.3413.3413

Published: 2007

Journal Articles

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

Martin H. Dreyling, MD, Roswitha Forstpointner, MD, Hans-Peter Boeck, MD, Roland Repp, MD, Hannes Wandt, MD, Christiane Pott, MD, John Francis Seymour, MD, Bernd Metzner, MD, Annette Haenel, MD, Tanja Lehmann, MD, Frank Hartmann, MD, Hermann Einsele, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 2769.

https://doi.org/10.1182/blood.V108.11.2769.2769

Published: 2006

Journal Articles

Increasing Frequency and Marked Stability of Complete Molecular Response Is Observed in Imatinib-Treated CML Patients with Long-Term Follow Up.

Susan Branford, John Francis Seymour, Andrew Grigg, Chris Arthur, Kevin Lynch, Timothy Hughes

Blood (2006) 108 (11): 430.

https://doi.org/10.1182/blood.V108.11.430.430

Published: 2006

Journal Articles

Ancestim (SCF) and High-Dose Twice-Daily Filgrastim (G-CSF) Is Superior to G-CSF Alone or Cyclophosphamide Plus G-CSF for Mobilization of Peripheral Blood Stem Cells (PBSC) in Patients with Indolent Lymphoproliferative Disorders Previously Treated with Fludarabine; Results of a Historically-Controlled Phase-II Study.

John Francis Seymour, MB, BS, PhD, Sue Morgan, MB BS, Miles Prince, MB BS MD, David Alan Westerman, MB BS, Max M. Wolf, MB BS, Dennis A. Carney, MB BS, Kally Yuen, MSc

Blood (2006) 108 (11): 3066.

https://doi.org/10.1182/blood.V108.11.3066.3066

Published: 2006

Journal Articles

Tissue Factor-Bearing Microparticles Derived from Tumor Cells: Impact on Coagulation Activation.

Monica Davila, PhD, Ali Amirkhosravi, PhD, Enriqueta Coll, PhD, Robles D. Liza, MS, John Francis, PhD

Blood (2006) 108 (11): 1757.

https://doi.org/10.1182/blood.V108.11.1757.1757

Published: 2006

Journal Articles

Prolonged Hematologic Toxicity from the Hyper-CVAD Regimen; Manifestations, Frequency, and Natural History in a Cohort of 125 Consecutive Patients.

Saar Gill, MBBS, Steven Lane, MBBS, Julie Crawford, MBBS, Peter Mollee, MBBS, Paula Marlton, MBBS, Gavin Cull, MBBS, Miles Prince, MBBS, MD, John Francis Seymour, MBBS, PhD

Blood (2006) 108 (11): 2441.

https://doi.org/10.1182/blood.V108.11.2441.2441

Published: 2006

NARROW

Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Comparison of Platelet-Activating Potential of Bevacizumab+VEGF and Aflibercept+VEGF Complexes

CDP7657, and Other Anti-CD40L Antibody Formats Lacking a Functional Fc Region, Do Not Cause Platelet Activation In Vitro

Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantilly Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.

Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.

A Prospective Study of the Prognostic Impact of 18 [F]-FDG-PET and Molecular Response in Patients with Relapsed Indolent Non-Hodgkin Lymphoma (NHL) Following Iodine-131-Rituximab Radio-Immunotherapy (RIT).

Repeat Treatment with Iodine-131-Rituximab Is Safe and Effective in Patients with Relapsed Indolent B-Cell Non-Hodgkin Lymphoma (NHL) Who Had Previously Responded to This Therapy.

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

Increasing Frequency and Marked Stability of Complete Molecular Response Is Observed in Imatinib-Treated CML Patients with Long-Term Follow Up.

Tissue Factor-Bearing Microparticles Derived from Tumor Cells: Impact on Coagulation Activation.

Prolonged Hematologic Toxicity from the Hyper-CVAD Regimen; Manifestations, Frequency, and Natural History in a Cohort of 125 Consecutive Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only